How Is Ajanta Pharma Driving Growth Through Branded Generics?

Ajanta Pharma’s focus on branded generics and specialty therapies continues to support steady growth across domestic and international markets.

Why Is Ajanta Pharma Strengthening Its Position In Branded Generics?

Ajanta Pharma Limited (AJP) is a specialty-driven pharmaceutical company with a strong footprint in branded generics across India, Asia, and Africa. The company has consistently delivered robust growth, leveraging a differentiated portfolio that covers therapies in cardiology, ophthalmology, dermatology, and pain management. Over the past three years, AJP has consistently outperformed the broader Nifty Pharma index, reinforcing investor confidence in its execution strategy.

Ajanta Pharma’s branded generics contributed 74% to FY25 revenues, with a CAGR of 12.5% achieved between FY22–25.

Ajanta Pharma: Strategy And Outlook

Brokerage coverage initiates with a Buy rating and a price target of ₹3,200. Analysts project a 13% revenue CAGR for FY25–28, supported by new therapeutic launches, deeper penetration into existing markets, and expansion in US generics. Domestic formulations accounted for 32% of FY25 turnover, underlining the strength of its India operations. The portfolio mix ensures sustainable growth as specialty therapies remain resilient and sticky.

The company recently entered nephrology and gynecology, while acquiring three brands in pain management, creating additional domestic growth drivers.

Looking ahead, management expects EBITDA/PAT CAGR of 17%/16% during FY25–28. Return ratios remain healthy with RoE at 28.5% and RoCE at 35.6% projected for FY27E. Trading at 24x P/E and 17x EV/EBITDA, valuations remain attractive given the strong visibility of earnings growth.

👉 For expert guidance on market trends, follow Nifty Tip | BankNifty Tip

Investor Takeaway

Ajanta Pharma continues to demonstrate strength in specialty therapies and branded generics. With a clear strategy of entering new therapies, expanding global presence, and maintaining superior margins, the company remains a compelling choice for investors seeking consistent growth opportunities in the pharma sector.

SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.

📌 Read more free updates at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.

tags: Ajanta Pharma analysis, Ajanta Pharma outlook, branded generics growth, pharma investment India, brokerage buy rating, specialty therapies expansion